# Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

Study · id `cardio:ct-nct07753200` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07753200](<https://clinicaltrials.gov/study/NCT07753200>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07753200

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3000 participants.

## Technical summary

Registry record NCT07753200. Randomized; single masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2031-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3000 participants (planned count; ClinicalTrials.gov record NCT07753200, source copy `cardio:ctgov-nct07753200-2026-08-10`, retrieved 2026-10-26)
- Started: 2026-07-20 (actual) (ClinicalTrials.gov record NCT07753200, source copy `cardio:ctgov-nct07753200-2026-08-10`, retrieved 2026-10-26)
- Primary completion: 2031-06-01 (anticipated) (ClinicalTrials.gov record NCT07753200, source copy `cardio:ctgov-nct07753200-2026-08-10`, retrieved 2026-10-26)
- Completion: 2031-12-31 (anticipated) (ClinicalTrials.gov record NCT07753200, source copy `cardio:ctgov-nct07753200-2026-08-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07753200, source copy `cardio:ctgov-nct07753200-2026-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07753200-2026-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
- Acronym: SMARTDECISION3
- Condition: Atrial Fibrillation (AF)
- Condition: Coronary Arterial Disease (CAD)
- Intervention (Drug): Edoxaban
- Intervention (Drug): Apixaban
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: cf4228458b32290da1157daeedcc253d86ca64162ddcfd9978a4864dc20977b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
